# US 2021/0171648 A1 · Antibodies and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171648 A1
- Document ID: US20210171648A1
- Status: Published application
- Kind: A1
- Application number: 17/077,456
- Filed: 2020-10-22
- Published: 2021-06-10
- Earliest claimed: 2015-12-02
- Assignees: Agenus Inc.; Memorial Sloan Kettering Cancer Center; Ludwig Institute for Cancer Research
- Applicants: Agenus Inc.; Memorial Sloan-Kettering Cancer Center; Ludwig Institute for Cancer Research Ltd.
- Inventors: Nicholas S. WILSON; Jeremy D. WAIGHT; Gerd RITTER; David SCHAER; Daniel HIRSCHHORN-CYMERMAN; Taha MERGHOUB; Ekaterina V. BREOUS-NYSTROM; Volker SEIBERT; Takemasa TSUJI; Olivier LÉGER; Dennis J. UNDERWOOD; Marc VAN DIJK
- Web page: https://patentgrep.com/patent/US20210171648A1

## CPC

- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C07K 16/30: from tumour cells
- A61K 2039/505: {comprising antibodies}
- C07K 2317/30: characterized by aspects of specificity or valency
- C07K 2317/31: multispecific
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies. In a specific aspect, the multispecific antibodies specifically bind to human GITR and OX40 and modulate GITR and/or OX40 activity, e.g., enhance, activate, or induce GITR and/or OX40 activity, or reduce, deactivate, or inhibit GITR and/or OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., enhances, activates, or induces GITR and/or OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., reduces, deactivates, or inhibits GITR and/or OX40 activity.

## Claims

### Claim at position 1

1-29. (canceled)

### Claim 30

A multispecific antibody comprising:
(a) a first antigen-binding region that specifically binds to human OX40 comprising
(i) a VH-CDR1 comprising the amino acid sequence of SEQ ID NO: 47;
(ii) a VH-CDR2 comprising the amino acid sequence of SEQ ID NO: 48;
(iii) a VH-CDR3 comprising the amino acid sequence of SEQ ID NO: 49;
(iv) a VL-CDR1 comprising the amino acid sequence of SEQ ID NO: 50;
(v) a VL-CDR2 comprising the amino acid sequence of SEQ ID NO: 51; and
(vi) a VL-CDR3 comprising the amino acid sequence of SEQ ID NO: 52 or 53; and
(b) a second antigen-binding region that specifically binds to human GITR comprising
(i) a VH-CDR1 comprising the amino acid sequence of X1YX2MX3 (SEQ ID NO: 87), wherein X1 is D, E or G; X2 is A or V; and X3 is Y or H;
(ii) a VH-CDR2 comprising the amino acid sequence of X1IX2TX3SGX4X5X6YNQKFX7X8 (SEQ ID NO: 88), wherein X1 is V or L; X2 is R, K or Q; X3 is Y or F; X4 is D, E or G; X5 is V or L; X6 is T or S; X7 is K, R or Q; and X8 is D, E or G;
(iii) a VH-CDR3 comprising the amino acid sequence of SEQ ID NO: 3;
(iv) a VL-CDR1 comprising the amino acid sequence of KSSQSLLNSX1NQKNYLX2(SEQ ID NO: 90), wherein X1 is G or S; and X2 is T or S;
(v) a VL-CDR2 comprising the amino acid sequence of SEQ ID NO: 5; and
(vi) a VL-CDR3 comprising the amino acid sequence of QNX1YSX2PYT (SEQ ID NO: 92), wherein X1 is D or E; and X2 is Y, F or S,
wherein the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 of the second antigen-binding region do not comprise the amino acid sequences of SEQ ID NOs: 7, 10, 3, 14, 5, and 16, respectively.

### Claim 31 (depends on 30)

The multispecific antibody of claim 30, wherein the second antigen-binding region comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 comprising the amino acid sequences of SEQ ID NOs: 8, 11, 3, 15, 5, and 17; 9, 12, 3, 14, 5, and 16; or 9, 13, 3, 14, 5, and 16, respectively.

### Claim 32 (depends on 30)

The multispecific antibody of claim 30, wherein:
(a) the first antigen-binding region comprises a VH comprising the amino acid sequence of SEQ ID NO: 54, and/or a VL comprising the amino acid sequence of SEQ ID NO: 55 or 56; and/or
(b) the second antigen-binding region comprises a VH comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 18, 20, 22, 24, and 25, and/or a VL comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 19, 21, 23, and 26.

### Claim 33 (depends on 30)

The multispecific antibody of claim 30, wherein the second antigen-binding region comprises a VH and a VL comprising the amino acid sequences of SEQ ID NOs: 20 and 21; 22 and 23; 24 and 23; or 25 and 26, respectively.

### Claim 34 (depends on 30)

The multispecific antibody of claim 30, wherein the first antigen-binding region and/or the second antigen-binding region comprises a heavy chain constant region selected from the group consisting of human IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2.

### Claim 35 (depends on 34)

The multispecific antibody of claim 34, wherein the heavy chain constant region is an IgG1 heavy chain constant region.

### Claim 36 (depends on 35)

The multispecific antibody of claim 35, wherein the heavy chain constant region comprises the amino acid sequence of SEQ ID NO: 126.

### Claim 37 (depends on 35)

The multispecific antibody of claim 35, wherein:
(a) the first antigen-binding region comprises a first heavy chain constant region comprising serine, alanine, and valine at amino acid positions 366, 368, and 407, respectively, and the second antigen-binding region comprises a second heavy chain constant region comprising tryptophan at amino acid position 366; or
(b) the first antigen-binding region comprises a first heavy chain constant region comprising tryptophan at amino acid position 366, and the second antigen-binding region comprises a second heavy chain constant region comprising serine, alanine, and valine at amino acid positions 366, 368, and 407, respectively,
numbered according to the EU numbering system.

### Claim 38 (depends on 37)

The multispecific antibody of claim 37, wherein the first heavy chain constant region and/or the second heavy chain constant region comprises aspartate, leucine, and glutamate at amino acid positions 239, 330, and 332, respectively, numbered according to the EU numbering system.

### Claim 39 (depends on 30)

The multispecific antibody of claim 30, wherein the first antigen-binding region comprises a first heavy chain comprising the amino acid sequence of SEQ ID NO: 54, and/or the second antigen-binding region comprises a second heavy chain comprising the amino acid sequence of SEQ ID NO: 25.

### Claim 40 (depends on 30)

The multispecific antibody of claim 30, wherein the first antigen-binding region and/or the second antigen-binding region comprises a light chain constant region selected from the group consisting of a human kappa light chain constant region or a human lambda light chain constant region.

### Claim 41 (depends on 30)

The multispecific antibody of claim 30, wherein the first antigen-binding region comprises a first light chain comprising the amino acid sequence of SEQ ID NO: 55, 56, 67, or 69, and/or the second antigen-binding region comprises a second light chain comprising the amino acid sequence of SEQ ID NO: 26.

### Claim 42 (depends on 30)

A pharmaceutical composition comprising the multispecific antibody of claim 30 and a pharmaceutically acceptable excipient.
